Precision Immuno-Oncology

Oct 10, 2024 | cell.com | Precision Immuno-Oncology |Lorenzo Galluzzi

1Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA 2Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA 3Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA 4National Center for Regenerative Medicine, Cleveland, OH, USA 5Case Comprehensive Cancer Center, Cleveland, OH, USA 6Italian Institute for Genomic Medicine, c/o IRCSS Candiolo, Torino, Italy 7Candiolo Cancer Institute, FPO -...

Jun 20, 2024 | academic.oup.com | Precision Immuno-Oncology |Hospitalet de Llobregat

The incidence of colorectal cancer (CRC) among individuals younger than age 50 (early onset CRC; EOCRC) has substantially increased, yet the etiology and molecular mechanisms underlying this alarming rise remain unclear. We compared tumor-associated T cell repertoires between EOCRC and average-onset CRC (AOCRC) to uncover potentially unique immune microenvironment-related features by age of onset.

Oct 30, 2023 | cell.com | Daniel J. McGrail |Precision Immuno-Oncology |Roger Smith

Highlights•Aberrations in known HR genes account for a small fraction of HR-deficient tumors•Integrated analysis identifies RNA-binding proteins as a driver of HR deficiency•RBP dysfunction can induce HR deficiency directly or via regulating HR repair genesSummaryDefects in homologous recombination DNA repair (HRD) both predispose to cancer development and produce therapeutic vulnerabilities, making it critical to define the spectrum of genetic events that cause HRD.